But I threw together some thoughts in about 10 mins or so -- (probably 30 now with posting to this forum)Questions for KK tomorrow - at present I'm not planning to ask them - others are welcome to if they wish
Phase 2 GVHD
- Is there anyreason why patient’s treated aren’t being reported as a number,1st , 2nd, 3rd etc rather than as apercentage (about 5%).
- Has the treatmentarm to control arm ratio been fixed? (ie 40 to treatment arm 20 tocontrol for a 2 to 1 ration or 30 to treatment arm 30 to control fora 1 to 1 ratio).
If not why not?
Is there any chancethat Cynata will need to raise funds to complete phase 2 in GVHD –or have the expenses for that discretionary undertaking by themanagement team already been fully paid for?
Recruiting – whyspend money recruiting a person to look at partnerships when thesubstantive value adding data that partners would be interested in(results from clinical trials) is still being generated? Isn’t thatpremature? Isn't it unfair to put a new hire into the money at 29cents if trial results come in that lift CYP above that through no work (on those trials) by the new hire?
MSB as a competitor
If MSB is granted aBLA for GVHD – what impact does Kilian see that having on orphandrug designation funding in the US if any – for instance does hethink it would be deemed the same drug by the FDA?
Does MSB’s patentgranted November 2023 in the US – entitled Mesenchymal Stem CellsExpressing TNF-alpha receptors constitute a problem for Cynata?
In the advent ofpatent offices granting patents too broadly to competitors doesCynata have the funds or the skills in management to do anythingabout that?
------------
I won't ask those, yet, (I see the main game currently as taking place between MSB and the FDA over GvHD BLA or not sooner than sculptor results or CYP phase 2 results) - so others can have them for nothing if they want to ask tommorow
I do think shareholders should get Kilian on the record about GvHD stuff - but experience suggests they (except for pfeifer) they won't and I expect Kilian would prefer to keep things rubbery and non specific.
- Forums
- ASX - By Stock
- CYP
- Rough thoughts in questions - help yourselves
CYP
cynata therapeutics limited
Add to My Watchlist
8.82%
!
18.5¢

Rough thoughts in questions - help yourselves
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
18.5¢ |
Change
0.015(8.82%) |
Mkt cap ! $41.80M |
Open | High | Low | Value | Volume |
17.5¢ | 18.5¢ | 17.0¢ | $21.36K | 121.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15599 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 27303 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 50585 | 0.170 |
4 | 141820 | 0.165 |
7 | 235931 | 0.160 |
7 | 385725 | 0.155 |
5 | 136379 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 27303 | 2 |
0.190 | 75000 | 1 |
0.195 | 6764 | 2 |
0.200 | 55400 | 2 |
0.205 | 6245 | 1 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
CYP (ASX) Chart |